Ethosuximide NDC 62135-790

NDC codes

FDA NDC Directory

Product NDC (as listed)62135-790Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62135-0790Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62135-790-12	62135079012	120 CAPSULE in 1 BOTTLE (62135-790-12)Marketed from Oct 23, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ethosuximide
Generic name (nonproprietary): ethosuximide
Active ingredients: Ethosuximide — 250 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Chartwell RX, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 200892
Marketing start: Sep 9, 2015
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 62135-790_24119078-bcee-0aa9-e063-6394a90af9c8SPL ID 24119078-bcee-0aa9-e063-6394a90af9c8SPL set ID 43fdfd16-c723-452a-9c1d-accf6f7c622eRxCUI 197682UNII 5SEH9X1D1DUPC 0362135790127
Pharmacologic class: Anti-epileptic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462135079012 followed by a unit qualifier and the quantity

Package 62135-0790-12. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 9, 2024.

Indications (excerpt from the label)

INDICATIONS AND USAGE Ethosuximide capsule is indicated for the control of absence (petit mal) epilepsy.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)